Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis - 21/08/11
Mark Lebwohl, MD, Mount Sinai School of Medicine, New York, NY, United States; Alice Gottlieb, MD, PhD, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, New Brunswick, NJ, United States; Wayne Wallis, MD, Ralph Zitnik, MD, Amgen, Thousand Oaks, CA, United States
Le texte complet de cet article est disponible en PDF. P2792 Dr Lebwohl is a investigator and consultant for Amgen/Wyeth and has received grant support and honoraria. Dr Gottlieb is an investigator, consultant, and member of the Speakers Bureau for Amgen. Research funded by Immunex Corporation, a wholly owned subsidiary of Amgen Inc., and by Wyeth Research. |
Vol 52 - N° 3S
P. P195 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?